Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.
Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is rolling out new data on a higher-dose injection in obesity. | In the phase 3b STEP UP study,
Meet ‘Super’ Ozempic: Higher Dose Semaglutide Leads to Even Greater Weight Loss In Major Trial
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.
Novo Nordisk's Ozempic & Wegovy in 2027 Medicare price talks
GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications. Seana Smith and Brad Smith break down the details on Morning Brief.
Novo Nordisk: STEP UP Trial Achieves Primary Endpoint - Quick Facts
Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary
Novo Nordisk stock drops on STEP UP trial results
Shares of Novo Nordisk (NYSE:NVO) fell 2% following the announcement of results from its STEP UP obesity trial, which showed that Semaglutide 7.2 mg achieved a 20.7% weight loss in participants, and 18.
1d
on MSN
White House says popular weight-loss drug Ozempic subject to Medicare talks
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker ...
valuepenguin
5d
Costs and Insurance Coverage for Ozempic, Wegovy & Weight Loss Drugs
Weight
loss
drugs like Ozempic and
Wegovy
cost an
average
of $1,083 per month if you pay full price or $325 per month after insurance. Find Cheap Health Insurance Quotes in Your Area
Weight
...
5d
'I feel blessed to get weight-loss jab' - but can the NHS afford it for all?
We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.
1d
on MSN
The Terrible—and Amazing—Side Effects of Weight Loss Drugs
GLP-1 drugs do a lot more than just help you lose weight. They can help your heart, brain, and more, but beware what they ...
FOX News on MSN
13d
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
With approximately 70% of American adults meeting the criteria for being obese or overweight, more people are turning to ...
1d
Mounjaro vs. Ozempic: Which One Is Best for Me to Try for Weight Loss in 2025?
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
1d
Explainer: What Wegovy's inclusion in Medicare price negotiation means for patients, company
The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback